Methods are provided for promoting longevity and decreasing the incidence of ageing associated pathologies (e.g. cancer) by the administration of one or more of the following LFFA: linoleic, oleic, and palmitic acid. Secondary LFFA derived from this set, as well as their coa derivatives and synthetic analogs, are effective also in promoting longevity and delaying the onset of age associated disorders. In addition, interventions including LFFA and coa LFFA formulations are described which protect the organism from acute physical stress, tissue damage, and hypoxia, either due to trauma or secondary to surgical procedures.
|
2. A method of enhancing tolerance of hypoxia associated with surgery comprising:
(a) selecting a mammal who is a surgical candidate,
(b) administering a long chain free fatty acid coa to said mammal prior to surgery by an acute course of therapy, wherein said long chain free fatty acid coa in an amount sufficient to achieve a systemic level which serves to provide said mammal with a signal equivalent to that experienced during caloric restriction, and
(c) whereby hypoxia tolerance is enhanced due to reduction in oxygen consumption.
1. A method of enhancing tolerance of hypoxia associated with surgery comprising:
(a) selecting a mammal who is a surgical candidate,
(b) administering a long chain free fatty acid coa to said mammal prior to surgery by an acute course of therapy, wherein said long chain free fatty acid coa is palmitoyl coa in an amount sufficient to achieve a systemic level which serves to provide said mammal with a signal equivalent to that experienced during caloric restriction, and
(c) whereby hypoxia tolerance is enhanced due to reduction in oxygen consumption.
3. A method of enhancing tolerance of hypoxia associated with surgery comprising:
(a) selecting a mammal who is a surgical candidate,
(b) administering a long chain free fatty acid coa to said mammal prior to surgery by an acute course of therapy wherein said long chain free fatty acid coa is linoleoyl coa, in an amount sufficient to achieve a systemic level which serves to provide said mammal with a signal equivalent to that experienced during caloric restriction, and
(c) whereby hypoxia tolerance is enhanced due to reduction in oxygen consumption.
|
|||||||||||||||||||||||||||||||||||||||||||||
This application is a continuation of PCT/US00/28322, filed Oct. 13, 2000, which claims priority to U.S. Application No. 60/159,099, filed Oct. 13, 1999.
1. Field of the Invention
This invention is directed to methods for increased longevity, delay of aging associated disorders, protection from acute physical stress and induction of regeneration and healing by administration of Long chain Free Fatty Acids (LFFA) and CoA derivatives of Long chain Free Fatty Acids (CoALFFA) in mammals.
2. Review of Related Art
Sixty years of active investigation has conclusively demonstrated that reduced caloric intake extends life span in a wide variety of animal species, including mammals (e.g., mice and rats) (Ingram, D. K. et al., “The Potential for Nutritional Modulation of the Aging Process,” Food and Nutrition Press (1991)). Moreover, the incidence of pathologies associated with aging in rodents are also delayed by caloric restriction (CR) (Roth, G. S. et al., Nature Medicine 1:414-415 (1995) and Weindruch, R., Scientific American: 46-52 (January 1996)) More recently, on-going CR studies using primates seem to mimic comparable biochemical changes observed in rodents (Roth, et al., 1995), and, by extension, the same effects should be expected to occur in humans subjected to caloric restriction.
Several hypotheses have been proposed to explain the mechanism(s) underlying the beneficial effects of CR, and some of these have been discarded. Today, it is accepted that the anti-aging effects of CR are not mediated by a retardation in growth and development, or by a reduction in body fat of animals subjected to caloric restriction. Still under investigation is the hypothesis that the beneficial effects of CR are due to a reduction in oxidative damage secondary to the generation of oxygen radicals (Weindruch, R., 1996). Support for this hypothesis is derived from studies demonstrating a reduction in lipid peroxidation and induction of the enzyme Superoxide Dismutase (Heydari, A. R. et al., Annals N.Y. Academy Science 663-384-395 (1992) and Yu, B. P., “Free Radicals in Aging” CRC Press (1993)) in animals subjected to caloric restriction. Another hypothesis that has received considerable attention attributes the beneficial effects of CR to the induction of “protective genes”. Investigators pursuing this hypothesis have demonstrated the induction of genes coding for SOD, HRP-70 and A2u-globulin and concluded that the effects of CR regulate gene expression at the transcriptional level (Heydari, A. R. et al., (1992). Most recently, using a genomics based approach to analyze gene expression in the skeletal muscles of aged and CR mice, it was proposed that CR retards the aging process by causing a metabolic shift resulting in increased protein turnover and decreased macromolecular damage (Lee, et al., 1999, Science, 285:1390-1393).
Although it is likely that protection against oxidative damage, and the induction of protective genes may play a role in the beneficial effects of CR, the underlying mechanism(s) involved remain a mystery.
This invention provides a method for improving the health of a mammal comprising administering to the mammal a composition comprising LFFA, CoALFFA, or other LFFA analogs in an amount sufficient to (a) inhibit thyroid hormone receptor binding in vivo, (b) inhibit Na/K ATPase and Ca ATPase in vivo, (c) conserve energy fuels, (d) reduce oxygen consumption in vivo, (e) cause a decrease in core body temperature in said mammal, and/or (f) activation of protective genes in vivo. The protective genes include p53, SOD, α-2-globulin, and/or HSP-70. Suitable-mammals include livestock, household pets, and especially humans. Preferred analogs of LFFA have enhanced half-lives in the circulation in the mammal. In preferred embodiments of this method, angiogenesis in the mammal is decreased, and/or hypoxia tolerance in the mammal is enhanced. This invention also provides compositions comprising LFFA, CoALFFA, or other LFFA analogs formulated for administering according to the method of this invention.
In one embodiment of this invention, the method comprises administering LFFA, CoALFFA, or other LFFA analogs to a human anticipating surgery, and the administration is carried out prior to surgery. In an alternative embodiment, the method comprises administering LFFA, CoALFFA, or other LFFA analogs to a mammal suffering from a condition characterized by hypoxia or an increased risk of local or systemic hypoxia.
The present invention relates to the use of LFFAs and CoALFFAs, either singly or in combination, to be provided either orally (as dietary supplements) or in pharmaceutical carriers (e.g., as slow-release implantables) to increase life span and to reduce the incidence and/or to delay the onset of pathologies associated with aging. The inventor has discovered that LFFAs and CoALFFAs mediate the increase in life expectancy and the reduction in aging associated disorders observed with caloric restriction in mammals. Moreover, the inventor has established that treatment of ad-libitum fed animals with LFFAs and CoALFFAs increases their life span and reduces the incidence of age associated disorders to rates comparable to those observed in calorie restricted animals. Apparently, LFFAs and CoALFFAs function as stress signals that trigger a stress/protective response, i.e., a series of protective mechanisms including: efficient utilization of alternate fuels, reduction in oxygen consumption, prevention of oxidative tissue damage, induction of heat shock proteins, activation of the cell cycle (promoting tissue regeneration and healing), as well as induction of DNA repair and anti-tumor genes.
Rationale of the Invention
While not wishing to be bound to any particular theory which might limit the scope of the present embodiment, the inventor has developed the following rationale for the present invention to explain and expand the observations. This rationale is based on the definition of CR as a form of mild to moderate starvation. Darwinian principles are the foundation of the logic employed that led to the present invention through the elucidation of metabolic and molecular mechanisms underlying the health benefits associated with CR.
The survival of all species, including the human animal, has depended on the ability to respond quickly to external challenges that compromise the biochemical integrity and life of the organism. In the wild, when a species is threatened by injury, disease or starvation, there is a built-in wisdom in nature that enables the organism to unleash biochemical signals that are involved in the conservation of energy fuels, in mounting an immune response, in cell cycle activation and tissue repair. Assuming a non-lethal event (whether injury, infectious disease or famine), eventually, the affected animal heals, or the disease runs its course, or food becomes plentiful once again, and the organism regains its health. The organism manages to survive in the absence of any medical intervention. Moreover, a benefit (survival and restored health) is harnessed from an apparent deficit. Therefore, against the conventional wisdom, we have to consider the following paradox: It appears that it is during episodes of catabolic stress that an animal is best suited to survive, to regenerate and to heal.
In this context, chronic CR may be perceived by the organism as a threat to its survival. CR is in biochemical terms a catabolic stress which, nonetheless, marshals several positive and protective mechanisms, including: 1) Blocking of thyroid hormone expression with a consequent reduction in oxygen consumption and the formation of harmful oxygen radicals, as well as conservation of energy fuels. 2) Inhibition of high energy ion channels (ATPases). 3) Induction of protective genes generating a powerful immune response. Therefore, the calorie restricted animal is better suited to survive injuries and to recover faster from disease. The net effect is a decrease in the incidence of ailments associated with aging and an overall slow-down of the aging process.
The present invention relates to factors involved in mediating the protective effects of CR, and the inventor's discovery of these factors was based on the premise that such factors would have to be selectively released during catabolic stress (potential candidates therefore included hormones, second messengers, intermediary metabolites, co-factors, etc.). In mammals, the sympatho-adrenal axis is activated in response to injury, disease, or starvation, resulting in the release of stress hormones (glucocorticoids and catecholamines) which together with low insulin-glucagon ratios promote increased levels of cAMP (Axelrod, J. et al., Science 224:452-459 (1984)). The resulting metabolic changes are swift and profound. Thyroid hormone levels are decreased, resulting in a condition often referred to as Euthyroid Sick Syndrome, that is, low thyroid hormones in the absence of clinical hypothyroidism (Wartofsky, L. et al., Endocrine Review 3:164-217 (1982)). Bioactive proteins (cytokines, lymphokines and growth factors) through complex signal transduction pathways, mediate gene expression resulting in cell cycle activation, tissue regeneration and restored health (Pardee, A. B., Science 246:603-608 (1989) and Laskey, R. A. et al., Science 246:609-614 (1989)). In view of the nature of CR, the inventor was able to focus on the effects of catabolic stress on energy metabolism. In calorie restriction (as well as during catabolic stress in general), lipolysis, ketogenesis and gluconeogenesis are favored over glycolysis and lipogenesis (Fain, J. M., et al., Adv. Exper. Med. Biol. 111:43-77 (1976)). Secondary to β-adrenergic stimuli, elevated levels of cAMP cause an activation of hormone sensitive lipase resulting in an immediate release of specific long chain free fatty acids from depot fat, including: Linoleic, oleic, and palmitic acids. These free fatty acids are increased in the circulation and in tissues where they are readily coupled to Coenzyme A (Seitz, H. J. et al., Diabetes 26:1159-1174 (1977)).
Observed Effects of Free Fatty Acids
The inventor has concluded that free fatty acids (LFFA) and/or their CoA derivatives are the factors which mediate the protective effects of CR in vivo for the following reasons: (see
1) Increased levels of FREE FATTY ACIDS and their CoA DERIVATIVES due to lipolysis are a common denominator in catabolic stress (Granot, C. et al., Isr. J. Med. Sci. 17:12 (1981); Flink, E. B. et al., Arch. Intern. Med. 141:441 (1981); Norbeck, H. E. et al., Acta. Med. Scand. 211:75 (1982); Helenius, T. et al., Scan J. Clin. Lab. Invest. 39:398; and Miles, J. M. et al., Clinics in Endocrin. and Metab. Saunders, Pa., vol. 12:303 (1983)). Moreover, mild to moderate starvation is also accompanied by increased levels of free fatty acids (Cahill, G. F., Clinics in Endocrin. and Metab. 5:397-415 (1976)). Most compelling is the fact that specific LFFAs (oleic, linoleic and palmitic acids) are elevated in calorie restricted rats (Liepa, G. U. et al., Am. J. Phys. 238:E253-E257 (1980)). The investigators reporting these results concluded that the expected age-dependent decline in these factors seen in ad-lib controls was somehow “delayed” by CR. According to the present invention, the interpretation of these results is that LFFAs are elevated in CR animals, and that these factors play a causal role in the beneficial effects associated with CR. Conversely, these factors are markedly reduced in anabolic states. In terms of caloric intake, in the wild, anabolic states would correspond to times of plenty and in the laboratory to ad-lib fed controls. Therefore, rather than being a mere consequence of catabolic events, LFFA are proposed to mediate the positive effects of CR.
2) The control of metabolic rate (the regulation of energy utilization, calorigenesis and oxygen consumption) are regulated by thyroid hormones in homeotherms (Guyton, A C., “Medical Physiology”, W. B. Saunders Co., Fifth Edition 1005 (1976)). Decreased thyroid hormone levels have been reported during starvation (Portray, G I, et al., J. Clin Endocr. Metab. 39:191-194 (1974)) and fasting (Vagenakis, A G., et al. J. Clin Endocr. Metab. 41:191-194 (1975)) in humans. Similarly, decreased thyroid hormone levels (Ingram, D K., et al., 1991) and lower core body temperature have been reported in rodents (Weindruch, R. H., et al., Fed. Proc. 38:2007-2016 (1979) and in primates (Lane, M A., et al., Proc. Nat. Acad. Sci 93:4159-4164 (1996)) subjected to CR. The inventor has concluded that elevated LFFA and CoALFFA are mediators of the beneficial effects of CR based on his previous studies demonstrating that these factors inhibit thyroid hormone synthesis (Chac∴n, M A., Doctoral Dissertation, Univ. of MD Graduate School (1985)), (see
3) Decreased thyroid hormone levels and hypothermia are a consequence of CR (Ingram, D K., et al. (1991), Weindruch, R H., et al., (1979), Lane, M A., et al., (1996)). As proposed by Hochachka (Science 231:234-241 (1986)), hypoxia-tolerant animals can sustain prolonged hypothermia by metabolic arrest and stabilized membrane functions. Inhibition of high energy ion channels (ATPases) may be coupled to lower metabolic need for ATP as a means to cope with limited energy substrates and low oxygen conditions.
A variety of important biological processes are mediated by the active transport of ions across membranes. These include: protein biosynthesis, energy metabolism and maintenance of action potentials across membranes. The active ion transport includes transport of Na, K, and Ca ions by transmembrane ATPases.
(I) Sodium-Potassium ATPase is a high energy requiring enzyme which maintains high K and low Na inside the cell against a concentration gradient. In terms of energy metabolism, this ion gradient permits the incorporation of glucose into cells and intracellular potassium is required for maximal activity of pyruvate kinase. Na,K ATPase has been reported to be inhibited by free fatty acids (Kelly, R A., et al., J. Biol. Chem., 261:11704-11711 (1986)). In the CR model of this invention, inhibition of Na,K ATPase by LFFAs would represent a net saving in energy (ATP) consumption but could also mediate other beneficial effects of CR.
(II) Calcium signals are involved in a variety of biological functions including secretory processes, muscle contraction, signal transduction, cell growth and the ability of cells to enter the cell cycle (Patterson, R L., et al., Cell 98:487-499 (1999), Berridge, M J., et al., Nature 395:645-648 (1998)). Intracellular calcium balance is maintained by Ca ATPase, an energy requiring transporter located in the sarcoplasmic/endoplasmic reticulum of cells (McLennan, D H., et al. Ann N. Y Acad. Sci. 671:1-10 (1992), Waldron, R T., et al., J. Biol. Chem 269:11927-11933 (1996)). Recent investigations have demonstrated a regulatory role of LFFA (Graber, M N., et al., J. Biol Chem. 271:883-888 (1996)) and CoALFFA (Rys-Sikora, K E., et al. J. Biol. Chem 269:31607-31613 (1994)) on Ca pools resulting in cell cycle activation. Extending these observations to the CR model, inhibition of Ca ATPase by LFFA and CoALFFA could result in energy conservation and a consequent rapid recovery from disease or injury that would contribute to a slowing of the aging process.
4) Serious exercise programs, such as those experienced by long distance runners and other similarly trained athletes, have been shown to decrease or to delay the onset of certain illnesses in humans (Hoffman-Goetz, L., “Excercise and Immune Function”, CRC Press (1996)). In terms of energy metabolism, one would expect similar changes as those observed in CR animal models (lower glucose, lower insulin-glucagon ratios, etc.). It is interesting to observe that the levels of thyroid hormones are reduced (O'Connell, M., et al., J. Clin Endocr. Metab. 49:242-246 (1979)) and the levels of LFFAs are elevated as a consequence of prolonged exercise in humans (Opstad, P K., et al., Clin. Endocr. 20:657-669 (1984),as well as in rats (Lefebvre, P J., Israel J. Med Sci. 8:390-398 (1972)), which is consistent with the observations in CR animal models.
5) The increase in the number of centenarians in industrialized societies has experienced a phenomenal increase over the last two decades, a development attributed to disease prevention and improved health care. However, it is intriguing that the apparent increase in life span is also coincident with the high consumption of vegetable oils (olive oil, canola oil, and avocado) which are rich in oleic, linoleic, linolenic and palmitic acids, which have been reported to be elevated in CR models.
6) LFFA are elevated in neonates and infants (Williamson, D H., et al., Dev. Neurosci. 15:156-164 (1993), Girard, J R., et al. Biochem. Soc. Transact. 9:344-345 (1981)) as well as the elderly. These stages of life are also characterized by hypoxia tolerance (Haddad, G G., et al., Annual Rev. Physiol. 436: 629 (1984)) and reduced incidence of disease in the former and slower progression of disease in the later.
Mimicking Effects of Caloric Restriction
In keeping with the rationale set forth above, the present invention provides therapeutic interventions which mimics the effects of CR. This is achieved by introducing LFFAs and/or derivatives thereof (FACTORS) into mammals so that these FACTORS are present systemically at levels having biological effects comparable to the LFFA levels generated during CR. Alternatively, therapeutic intervention may be given which results in endogenous release of LFFAs from tissue stores. By achieving systemic levels of these FACTORS which compare with the levels generated during CR, the stress/protective responses are activated, with concomitant benefits for the organism.
The FACTORS
According to the method of this invention, one or more compounds (FACTORS) are administered to a mammal to achieve a systemic level which serves to provide the mammal with a signal equivalent to that experienced during CR. Suitable compounds include the LFFA (palmitic, oleic, linoleic, and linolenic acids), as well as the CoA adducts of these fatty acids (CoALFFA). In addition, analogs of these fatty acids which perform the same signaling function may be used. Such analogs will meet one or more of the in vitro and in vivo tests described in the Examples for evaluating FACTORS. Suitable analogs may be selected from the metabolic products of LFFA (gamma-linolenic acid (18:3n6), dihomo-gammalinolenic acid (20:3n6), arachidonic acid (20:4n6), eicosapentaenoic acid (20:5n3), docosahexaenoic acid (22:6n3), as well as fatty acids designated 18:4n3, 20:4n3, 22:4n6, 22:5n3, and 22:5n6, see, e.g., Stewart, et al., U.S. Pat. No. 4,826,877), non-hydrolyzable CoA analogs, such as S-(2-oxoalkyl)-CoA, where alkyl may be from 14-22 carbons, exemplified by S-(2-oxopentadecyl)-CoA), esters of the fatty acids and LFFA analogs (including alkyl esters, especially C1-3 alkyl, glycerol mono-, di-, and tri-esters, phosphoglycerol esters, etc.), or derivatives of LFFA which have greater stability and/or half-life in the circulatory system (e.g., reaction products which limit the reactivity of the unsaturated bonds in the aliphatic chain of the fatty acid without changing the configuration of the chain in regions critical to signaling). In addition, compounds including β-adrenergic agonists, e.g., isoproterenol, as well as direct effectors of hormone sensitive lipase (these may include small molecule activators as well as inhibitors of metabolism of the enzyme or other materials which preserve or enhance in vivo activity of the enzyme) may be used.
Administration of the Components
Therapeutic compounds according to this invention are preferably formulated in pharmaceutical compositions containing the compound and a pharmaceutically acceptable carrier. The pharmaceutical composition may contain other components so long as the other components do not reduce the effectiveness of the compound according to this invention so much that the therapy is negated. Pharmaceutically acceptable carriers are well known, and one skilled in the pharmaceutical art can easily select carriers suitable for particular routes of administration (Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, Pa., 1985).
The pharmaceutical compositions containing any of the compounds of this invention may be administered by parenteral (subcutaneously, intramuscularly, intravenously, intraperitoneally, intrapleurally, intravesicularly or intrathecally), topical, oral, rectal, or nasal route, as necessitated by choice of drug. The concentrations of the active agent in pharmaceutically acceptable carriers may range from 0.01 mM to 1 M or higher, so long as the concentration does not exceed an acceptable level of toxicity at the point of administration. The dose used in a particular formulation or application will be determined by the requirements of the particular type of disease and the constraints imposed by the characteristics and capacities of the carrier materials.
Dose and duration of therapy will depend on a variety of factors, including therapeutic index of the drug(s), as well as the subject's condition, age, weight, and tolerance of toxicity. Dose will generally be chosen to achieve serum concentrations from about 0.2 mM to about 2 mM. Preferably, initial dose levels will be selected based on their ability to achieve ambient concentrations shown to be effective in in vitro and in vivo models, such as those described herein, and in clinical trials, up to maximum tolerated levels. Typically, the dose will be selected to achieve a systemic increase in circulating LFFA of from 1.5× to 5×, or an equivalent level of another signaling compound. The dose of a particular drug and duration of therapy for a particular subject can be determined by the skilled clinician using standard pharmacological approaches in view of the above factors. The response to treatment may be monitored by analysis of blood or body fluid levels of the compound according to this invention, measurement of activity of the compound or its levels in relevant tissues or other clinical parameters based on standard monitoring techniques for determining the physiological state of the subject. For example, serum levels of LFFA may be quantitated by thin layer chromatography, Gas chromatography-mass spectroscopy, and/or high pressure liquid chromatography. Other relevant parameters include body temperature, metabolic rate (which may be determined by calorimetry), and thyroid hormone level (i.e., T3, which may be determined by radioimmunoassay, ELISA, etc.), as well as lowering of Na—K ATPase in blood cells. The skilled clinician will adjust the dose and duration of therapy based on the response to treatment revealed by these measurements.
A particularly preferred formulation for compounds according to this invention is in liposomes. Liposomes containing compounds according to this invention may be prepared by any of the methods known in the art for preparation of liposomes containing inclusions. Liposomes that are particularly suited for aerosol application to the lungs are described in International Patent Publication WO 93/12756, pages 25-29, incorporated herein by reference.
The compositions described above may be combined or used together or in coordination with another therapeutic substance.
Indications for this Method
The method of this invention applies generally to mammals, including livestock and household pets, and especially humans. The general population are candidates for therapy according to this invention for delay of the onset of aging and aging related disease. Chronic administration of one or more compounds according to this invention to individuals with no identified disease syndrome or health problem is within the contemplation of this invention. The method of this invention may also be beneficial to certain disease states in which the use of LFFA and derivatives is not counterindicated. Preferably, the method of this invention may be used to activate the stress/protective effect in any mammal in need thereof.
Surgical candidates may be treated prior to surgery by an acute course of therapy according to this invention to activate the stress/protective response. Typically, such administration will be initiated before surgery and will continue until the desired systemic level of the signaling molecules is achieved and/or until the stress/protective response is activated, as demonstrated by one or more of the responses discussed above, such as body temperature, metabolic rate, thyroid hormone levels or Na—K ATPase activity. The described intervention may also be used during surgery concomitantly with current methods for extracorporeal circulation (i.e., heart-lung machines) in order to achieve metabolic arrest and reduced oxygen consumption without need for the excessive chilling currently used in open-heart and neurosurgical procedures.
Similarly, activation of the stress/protective response in the absence of an identifiable disease state may be of value for soldiers or athletes who can anticipate traumatic injuries in the ordinary course of their expected activities. Administration of FACTORS according to this. invention may be beneficial for animals (including humans) which are (or are expected to be) exposed to hypoxia. Administration of factors in an amount sufficient to induce a stress/protective response provides some degree of protection against adverse effects of hypoxia, and therefore the invention contemplates treatment for situations involving high altitude, undersea, or outerspace operations, or in the clinics for conditions associated with acute or chronic hypoxia, such as angina, cerebrovascular, myocardial or peripheral vascular insults, pulmonary embolism or heart failure.
Finally, the beneficial effects of FACTORS in inducing protection and regeneration may also be apparent when applied locally. Therefore, topical application of FACTORS may have a cosmetic or anti-wrinkling effect in humans.
Numerous physiological systems are affected by the compounds which mediate the CR response. Certain of these systems may be isolated and observed in vitro, and these systems provide in vitro methods for demonstrating the effect of known FACTORS or confirming the activity of previously unknown FACTORS. The values obtained in the presence and absence of FACTORS will be determined, and the value for a candidate FACTOR may be compared to the value for LFFA or LFFACoA.
1. Thyroid hormone receptor binding will be performed as described by Li, et al., (Li Q., et al., J. Biochem. 107:699-702 (1990), Li Q., et al., J of Cell Biochem 51:458-464 (1993)) using purified liver receptor protein derived from Ad Lib fed rats. Binding of 125I-T3 to its receptor protein is measured in the presence of 5-50 μM candidate FACTORS. FACTORS will inhibit binding of T-3 to its receptor.
2. Na/K ATPase activity will be performed in the presence and absence of FACTOR using commercially available enzyme as described by Kelly, R A., et al., J. Biol. Chem., 261:11704-11711 (1986). FACTORS will inhibit the hydrolysis of [γ-32P] ATP and/or [3H]-ouabain binding to Na—K ATPase.
3. Ca ATPase activity will be performed in the presence and absence of FACTOR using DDTIMF2 cells in culture (Rys-Sikora, K E., et al., J. Biol. Chem. 269:31607-31613 (1994)). FACTORS will inhibit GTP-activated Ca2+-release by saponin-permeabilized cells.
4. Effect of FACTORS on the induction of protective genes (e.g., p53, SOD, α-2-globulin, HSP-70) may be determined by comparing the expression of protective genes in isolated hepatocytes incubated in the presence and absence of the FACTOR or candidate FACTOR. Expression will be increased in the presence of FACTORS such as LFFA, and demonstration of an increase in expression of these protective genes indicates that the candidates are indeed FACTORS or analogs of FACTORS. Gene induction may be quantified by Northern Analysis, RTPCR (Heydari, A R., et al., Annals N.Y. Academy Science 663:384-395 (1992)) and/or by oligonucleotide microarray (Lee, C., et al., Science 285:1390-1393 (1999)).
To further confirm the results of in vitro tests (Example 1) or for use as independent screening assays for candidate FACTORS, biochemical parameters and genetic markers, as well as indices of metabolism, will be compared in rodent populations either fed (i) ad lib, (ii) calorie restricted or (iii) ad lib but treated with experimental (candidate) factors. Animals will be treated for approximately three months. During the treatment period, the following tests will be performed.
1. Core body temperature will be performed weekly (Lane, M A., et al., Proc. Nat. Acad. Sci. 93:4159-4164 (1996)).
2. Indirect calorimetry (O2 consumption) will be performed weekly (Lane, et al., 1996).
3. Biochemical studies (thyroid hormone binding, Na/K and Ca ATPase activity) will be performed using tissues of animals sacrificed at the beginning, middle (45 days) and end (90 days) of the study (Li Q., et al., J. Biochem. 107:699-702 (1990), Li Q., et al., J of Cell Biochem 51:458-464 (1993), Kelly, R A., et al., J. Biol. Chem., 261:11704-11711 (1986),Rys-Sikora, K E., et al., J. Biol. Chem. 269:31607-31613 (1994)).
4. Protective gene induction will also be performed on animals sacrificed as in preceding paragraph 3 (Heydari, A R., et al., Annals N.Y. Academy Science 663:384-395 (1992); Lee, C., et al., Science 285:1390-1393 (1999)).
1. Delay of the onset of pathologies may be demonstrated for the age-related incidence of cancer in a susceptible animal model. A cancer susceptible strain of mice (p53 knockout) will be used for these studies (Perkins, S. N., et al., Carcinogenesis 18: 989-994 (1997); Hursting, S. D., et al., Proc. Natl. Acad. Sci. 91: 7036-7040 (1994). The incidence of tumors will be monitored in groups of mice fed ad lib, calorie restricted or fed ad lib but treated with factors.
2. Life span will be determined in groups of rats fed ad lib, calorie restricted or fed ad lib/treated with factors.
The effects of FACTORS and analogs of FACTORS may be tested in the following systems.
1. Hypoxia tolerance will be tested in ad lib fed rats as described by Haddad (Haddad, G G., et al., Annual Rev. Physiol. 46:629 (1984)) +/−factors.
2. Preoperative protection will be tested by subjecting ad lib fed rats +/−factors to a surgical procedure and establishing the rate of recovery (monitoring clinical and/or functional parameters relevant to the surgery). Surgical procedures include: A. Renal model of Ischemia—reperfussion (Bonventre, J. V., Ann. Rev. Med. 39: 531-544 (1988)) and B. Sciatic nerve crush injury (Wang, M. S., et al., J. Pharmacol. Exp. Therapeut., 282: 1083-1093 (1997)).
3. Effect of factors on angiogenesis will be tested using the Matrigel Angiogenesis model in C57 mice (Passaniti, A., et al., Lab. Invest. 67: 519-528 (1992)).
For purposes of clarity of understanding, the foregoing invention has been described in some detail by way of illustration and example in conjunction with specific embodiments, although other aspects, advantages and modifications will be apparent to those skilled in the art to which the invention pertains. The foregoing description is intended to illustrate, but not limit the scope of the invention. Modifications of the above-described modes for carrying out the invention that are apparent to persons of skill in medicine, immunology, nutrition, endocrinology, pharmacology, and/or related fields are intended to be within the scope of the invention, which is limited only by the appended claims.
All publications and patent applications mentioned in this specification are indicative of the level of skill of those skilled in the art to which this invention pertains. All publications and patent applications mentioned above are herein incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference.
| Patent | Priority | Assignee | Title |
| Patent | Priority | Assignee | Title |
| 4752618, | Jul 12 1984 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC , THE | Method of minimizing efects of infection through diet |
| 4826877, | Oct 02 1985 | Efamol Limited | Pharmaceutical and dietary composition |
| 4871768, | Jul 12 1984 | New England Deaconess Hospital Corporation | Dietary supplement utilizing ω-3/medium chain trigylceride mixtures |
| 4879312, | Mar 07 1988 | Angio-Medical Corporation | Method for enhancing or provoking angiogenesis using angiogenically active omega-3 polyunsaturated fatty acids |
| 5043328, | May 09 1986 | Hoechst Aktiengesellschaft | Formulations containing unsaturated fatty acids for the synthesis of prostaglandins and hydroxy-fatty acids in biological systems |
| 5164414, | Jan 25 1990 | Adir et Compagnie | Use of N-myristoyl-(S)-phenylalanine for the treatment of diseases involving myristoylation |
| 5221668, | Feb 26 1992 | Abbott Laboratories | Nutritional product for trauma and surgery patients |
| 5223285, | Mar 31 1992 | Abbott Laboratories | Nutritional product for pulmonary patients |
| 5231085, | Oct 31 1988 | Nestec S A | Compositions and methods for the enhancement of host defense mechanisms |
| 5260336, | Apr 30 1992 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC , THE | Monounsaturated fat as dietary supplement to minimize the effects of catabolic illness |
| 5397701, | Oct 12 1990 | RESEARCH CORPORATION TECHNOLOGIES, INC | Azido-substituted fatty acid analog enzyme substrates |
| 5541225, | Oct 11 1994 | General Hospital Corporation, The | α-Linolenic acid and eicosatetraynoic acid in the prevention and treatment of ventricular tachyarrhythmia |
| 5571689, | Jun 16 1988 | RESEARCH CORPORATION TECHNOLOGIES, INC | Method of N-acylating peptide and proteins with diheteroatom substituted analogs of myristic acid |
| 5709863, | Feb 03 1995 | Properties of cats' facial pheromones | |
| 5731346, | Feb 24 1992 | Fresenius Kabi AB | Use of omega-3-fatty acids |
| 5747533, | Feb 24 1992 | Fresenius Kabi AB | Use of ω-3-fatty acids |
| 5767156, | Oct 06 1993 | CHILDREN, YOUTH AND WOMEN S HEALTH SERVICE INCORPORATED; Peptide Technology Limited; CHILDREN S YOUTH AND WOMEN S HEALTH SERVICE INCORPORATED | Polyunsaturated fatty acids and uses thereof |
| 5780237, | Oct 12 1994 | Cell Therapeutics, Inc.; CELL THERAPEUTICS, INC | Sepsis, adult respiratory distress syndrome, and systemic inflammatory response syndrome diagnostic |
| 5871954, | Feb 03 1988 | Washington University | Fatty acid analog enzyme substrates |
| 6034132, | Jan 05 1998 | Aker Biomarine ASA | Method of reducing bodyweight and treating obesity |
| 6036992, | Mar 28 1997 | Abbott Laboratories | Process of making an enteral formula containing long-chain polyunsaturated fatty acids |
| 6054481, | Jan 21 1998 | Fideline | Pig appeasing pheromones for enhancing weight gain in a mammal |
| 6077867, | Jan 21 1998 | Fideline | Pig appeasing pheromones to decrease stress, anxiety and aggressiveness |
| 6169113, | Jan 21 1998 | Pig appeasing pheromones to decrease stress, anxiety and aggressiveness | |
| 6365628, | May 08 1998 | BERGEN TEKNOLOGIOVERFØRING AS | Fatty analogues for the treatment of diabetes |
| 6380253, | Jan 05 2000 | EFA Sciences LLC | Method of stabilizing and potentiating the action of anti-angiogenic substances |
| 6384252, | Jan 21 1998 | Fideline | Animal appeasing pheromones |
| 6395782, | Mar 02 2001 | Wisconsin Alumni Research Foundation | Method of increasing longevity and preventing body weight wasting in autoimmune disease by using conjugated linoleic acid |
| 6441036, | May 08 1998 | BERGEN TEKNOLOGIOVERFØRING AS | Fatty analogues for the treatment of obesity, hypertension and fatty liver |
| CA2318392, | |||
| EP71357, | |||
| EP635267, | |||
| JP3297364, | |||
| JP60025934, | |||
| JP7267864, | |||
| WO117524, | |||
| WO9312756, | |||
| WO9816215, |
| Executed on | Assignor | Assignee | Conveyance | Frame | Reel | Doc |
| Oct 25 2010 | CHACON, MARCO | PARAGON BIOSCIENCES, INC | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 025192 | /0336 |
| Date | Maintenance Fee Events |
| Feb 21 2012 | M2551: Payment of Maintenance Fee, 4th Yr, Small Entity. |
| Apr 01 2016 | REM: Maintenance Fee Reminder Mailed. |
| Aug 19 2016 | EXP: Patent Expired for Failure to Pay Maintenance Fees. |
| Date | Maintenance Schedule |
| Aug 19 2011 | 4 years fee payment window open |
| Feb 19 2012 | 6 months grace period start (w surcharge) |
| Aug 19 2012 | patent expiry (for year 4) |
| Aug 19 2014 | 2 years to revive unintentionally abandoned end. (for year 4) |
| Aug 19 2015 | 8 years fee payment window open |
| Feb 19 2016 | 6 months grace period start (w surcharge) |
| Aug 19 2016 | patent expiry (for year 8) |
| Aug 19 2018 | 2 years to revive unintentionally abandoned end. (for year 8) |
| Aug 19 2019 | 12 years fee payment window open |
| Feb 19 2020 | 6 months grace period start (w surcharge) |
| Aug 19 2020 | patent expiry (for year 12) |
| Aug 19 2022 | 2 years to revive unintentionally abandoned end. (for year 12) |